Finland
RNatives is a biotechnology startup focused on developing innovative nuclear microRNA-technology for the treatment of cardiovascular diseases. Utilizing the novel biology of nuclear microRNAs, the company aims to modulate the gene expression of desired target genes. Its current primary objective is to upregulate the endogenous VEGFA-gene, with the aim of treating diseases such as myocardial ischemia and peripheral artery disease. By upregulating the cell's own VEGFA through small RNA, RNatives aims to induce neovascularization and facilitate recovery from the disease condition. The proprietary platform technology is based on years of academic research published by Turunen et al.
At present, essential details such as the company’s founding date, headquarters, last investment, and investors are not known. Nevertheless, RNatives’ focus on cutting-edge gene therapy for cardiovascular diseases, as well as its reliance on genuine scientific research, positions it as a notable player in the biotechnology and health care industries, making it an intriguing prospect for potential venture capital investment.
